Somnair Secures $4.3 Million in Seed Funding for Innovative Sleep Apnea Device

Somnair, a startup based in Towson, Md., has successfully raised $4.3 million in seed funding to further develop its innovative device aimed at managing obstructive sleep apnea (OSA). This funding, as detailed in an SEC filing, represents a pivotal moment in tackling a healthcare issue that impacts approximately 54 million Americans. The founders, alumni of the Johns Hopkins Whiting School of Engineering's Biodesign program, have combined their expertise to devise a solution for patients who struggle with the discomfort of traditional continuous positive airway pressure (CPAP) therapy or are unsuitable candidates for surgery.

The device, resembling a mouth retainer, employs neurostimulation to activate a nerve responsible for controlling muscle movements in the palate and throat, thereby facilitating easier breathing during sleep. This novel approach has garnered early support from MedStar Health, following Somnair's showcase at Towson University's 2024 StarTUp Accelerator. Preliminary findings from a proof-of-concept study involving 22 participants have shown encouraging results, suggesting that Somnair's technology could significantly alter the treatment paradigm for OSA. By providing an alternative for those who cannot endure CPAP, the device has the potential to mitigate the risk of chronic conditions linked to OSA, such as heart disease and diabetes.

For more information on the impact of obstructive sleep apnea and current treatment options, visit https://www.sleepapnea.org. This breakthrough underscores the importance of innovation in addressing widespread health challenges, offering hope to millions affected by OSA.